07:58 AM EST, 11/12/2024 (MT Newswires) -- BridgeBio Pharma ( BBIO ) reported a Q3 loss Tuesday of $0.86 per diluted share, narrowing from a loss of $1.08 a year earlier.

Three analysts surveyed by Capital IQ expected a loss of $0.98.

Revenue for the quarter ended Sept. 30 was $2.7 million, down from $4.1 million a year earlier.

Analysts surveyed by Capital IQ expected $3.4 million.